1. Jing Guo¹, Haotian Tang¹, Wenchao Zhao¹, Shukai Song, Fang Feng, Shengjie Huang, Xuan Wang, Yang Zhou, Junping Pei,Dong Guo^*,Hua Xie^*, Xiaoyun Lu^*. Discovery of TBK1 Molecular Glue Degraders as a Potential Strategy for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Journal of Medicinal Chemistry, (in press, ¹ co-first author)

2. Jing Guo¹, Xiaojuan Chen¹, Xiaofei Li, Min Shao, Xiaojuan Song, Lin Zhang, Shengjie Huang, Adam V. Patterson, Jeff B. Smaill,Yang Zhou,Xiangrong Yu^*, Yongheng Chen^*, Xiaoyun Lu^*. Optimization of AminoindazoleDerivatives as Highly Selective Covalent Inhibitors for Wild-Type and MutantFGFR4. Bioorganic chemistry, 160 (2025), 108469. (¹ co-first author)

3. Jing Guo¹, Shuang Xiang¹, Jie Wang¹, YangZhou, Zuqin Wang, Zhang Zhang*, Ke Ding*, Xiaoyun Lu*. Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, preliminary SAR and the binding mode validation via molecular dynamics simulation. European Journal of Medicinal Chemistry,228 (2022), 114022.

4.Jing Guo, TingtingWang, TianxiaoWu, Kehan Zhang, Wenbo Yin, Mingyue Zhu, Yu Pang, Chenzhou Hao, Zhonggui He, Maosheng Cheng, Yang Liu*, Jiang Zheng, Jingkai Gu*, Dongmei Zhao*. Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor. European Journal of Medicinal Chemistry, 186 (2020), 111878.

5.Jing Guo¹, Fan Zhao¹, Wenbo Yin, MingyueZhu, Chenzhou Hao, Yu Pang, Tianxiao Wu, Jian Wang, Dongmei Zhao*, Haitao Lib*, Maosheng Cheng*. Design, synthesis, structure-activity relationship study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors. European Journal of Medicinal Chemistry,155 (2018), 197-209. (¹ co-first author)

6.Minhao Huang¹, Yongjun Huang¹,Jing Guo¹, Lei Yu, Yu Chang, XiaoluWang, Jinfeng Luo, Yanhui Huang, Zhengchao Tu, Xiaoyun Lu, Yong Xu, Zhimin Zhang*, Zhang Zhang*, Ke Ding*. Pyrido [2, 3-d] pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. European Journal of Medicinal Chemistry, 211 (2021), 113023. (¹ co-first author)

7.Jing Guo, Mingyue Zhu, Tianxiao Wu, Chenzhou Hao, Kai Wang, Zizheng Yan, Wanxu Huang, Jian Wang, Dongmei Zhao*, Maosheng Cheng*. Discovery of indolin-2-one derivatives as potent PAK4 inhibitors:Structure-activity relationship analysis, biological evaluationand molecular docking study. Bioorganic & Medicinal Chemistry,25 (2017), 3500 -3511.

8.Jing Guo, Zhen Zhang, Ke Ding*. A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present), Expert Opinion on Therapeutic Patents, 30 (2020), 341-350.

9.Jing Guo, Yang Zhou, Xiaoyun Lu*. Advances in protein kinase drug discovery through targeting gatekeeper mutations, Expert Opinion on drug discovery, 18 (2023), 1349-1366.

10.Jintong Du¹,Jing Guo¹, Dongwei Kang¹, Zhihong Li¹, Guan Wang¹, Jianbing Wu¹, Zhen Zhang, Hao Fang*, Xuben Hou*, Zhangjian Huang*, Guobo Li*, Xiaoyun Lu*, Xinyong Liu*, Liang Ouyang*, Li Rao*, Peng Zhan*, Xiaojin Zhang*, YihuaZhang*. New techniques and strategies in drug discovery. Chinese Chemical Letters, 31 (2020), 1695-1708. (¹ co-first author)